» Articles » PMID: 31306125

Immunoglobulin Genes and Immunity to HSV1 in Alzheimer's Disease

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2019 Jul 16
PMID 31306125
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Although genome-wide association studies (GWAS) of late-onset Alzheimer's disease (AD) have identified numerous genes that influence the risk for disease, the majority of the genetic variance of AD remains uncharacterized. Furthermore, current GWAS, despite their name, do not evaluate all genes in the human genome. One such gene complex is immunoglobulin GM (γ marker) genes on chromosome 14. GM genes are excellent candidate genes for AD because they influence immunity to herpes simplex virus type 1 (HSV1), which has been implicated in AD pathology by an increasing number of reports. The aim of this investigation was to determine if particular GM genotypes were associated with AD and mild cognitive impairment (MCI), and whether they contributed to the interindividual differences in the level of anti-HSV1 IgG antibodies. A total of 141 HSV1 seropositive individuals-56 AD patients, 48 MCI individuals, and 37 sex- and age-matched healthy controls-were characterized for GM alleles 3, 17, and 23. The homozygosity for the GM 3 allele was significantly associated with MCI (p = 0.025). GM 3/17 heterozygous AD patients had significantly higher levels of anti-HSV1 antibodies than the healthy controls expressing the same genotype (p = 0.0004). Among MCI subjects, the GM 3/17 genotype was associated with significantly higher level of anti-HSV1 antibodies as compared to the GM 17/17 homozygous genotype (pc = 0.040). Among AD patients, the GM 23+/-genotype was significantly associated with anti-HSV1 antibody responses (pc = 0.025). These results suggest that GM genes could act as potential unifiers of the genetic and viral etiology of AD.

Citing Articles

Immunoglobulin genes and severity of COVID-19.

Vazquez-Coto D, Kimball C, Albaiceta G, Amado-Rodriguez L, Garcia-Clemente M, Gomez J Immunogenetics. 2024; 76(3):213-217.

PMID: 38602517 PMC: 11087305. DOI: 10.1007/s00251-024-01341-z.


Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.

Awan S, Pegu A, Strom L, Carter C, Hendel C, Holman L JCI Insight. 2024; 9(7).

PMID: 38587079 PMC: 11128198. DOI: 10.1172/jci.insight.175375.


Herpes Simplex Viral Infection Doubles the Risk of Dementia in a Contemporary Cohort of Older Adults: A Prospective Study.

Vestin E, Bostrom G, Olsson J, Elgh F, Lind L, Kilander L J Alzheimers Dis. 2024; 97(4):1841-1850.

PMID: 38306033 PMC: 10894565. DOI: 10.3233/JAD-230718.


Herpes simplex virus infection and the risk of dementia: a systematic review and meta-analysis.

Elhalag R, Motawea K, Talat N, Rouzan S, Mahmoud N, Hammad E Ann Med Surg (Lond). 2023; 85(10):5060-5074.

PMID: 37811098 PMC: 10552998. DOI: 10.1097/MS9.0000000000000951.


GM Allotypes and COVID-19. A Pilot Study Performed on Sicilian Patients.

Ligotti M, Calabro A, Accardi G, Aiello A, Caruso C, Colomba C Transl Med UniSa. 2023; 24(2):26-29.

PMID: 37476201 PMC: 10354864. DOI: 10.37825/2239-9747.1039.